DT MedTech Acquires Worldwide Ownership of Hintermann Series of Lower Extremity Replacement and Revision Medical Devices

DT MedTech, LLC (DTMT) announced today that it has successfully completed the acquisition of ownership of the Hintermann Series lower extremity device product line. Developed by prominent surgeon, Professor Beat Hintermann, this exceptional product line includes: (1) the Hintermann Series H3 3-piece Total Ankle Replacement prosthesis (formerly known as the HINTEGRA Total Ankle Replacement prosthesis), including a revision platform, and a system available for patients with sensitivities to Cobalt-Chrome alloys; (2) the Kalix II, a subtalar arthroereisis implant to treat flatfoot deformities; and (3) instrumentation and consumables to support the implantable devices.

As of May 1, 2016, DTMT will have the exclusive rights to manufacture, distribute, import, export, market, and sell the entire Hintermann Series product line. Current manufacturers, who have been producing the Hintermann Series products for the past 10 years, will continue to manufacture all products for DTMT, and Healthlink Europe will handle the majority of logistics outside of the United States. Currently, the product line is only available outside of the US.

Dr. David Reicher, president and chief executive officer of DTMT, stated, “Our ownership of this superior, clinically-proven line of the Hintermann Series medical devices marks an important milestone for DT MedTech, as we begin to position ourselves as a global leader in lower extremity surgical solutions. Working diligently alongside Professor Beat Hintermann, we plan to expand worldwide distribution of the Hintermann Series H3 Total Ankle Replacement and will introduce Professor Hintermann’s innovative, 2-piece total ankle replacement device in the very near future. We want to assure all surgeons who currently use these products that the newly acquired devices will remain exactly the same in structure and materials. Additionally, we foresee no disruption in terms of product availability.”